Agilent Aims Higher: Solid Q1 2026 Ups its Revenue Forecast and Non-GAAP EPS Path

Agilent Technologies, Inc. (NYSE: A) kicked off fiscal year 2026 with a respectable salvo: first-quarter revenue of about $1.80 billion, a GAAP net income of $305 million, and earnings per share (EPS) of $1.07. On a non-GAAP basis, the company posted net income of $386 million and non-GAAP EPS of $1.36. The numbers line up with a company that is growing in a market that hasn’t yet run out of students for the chemistry lab. In plain English, the top line moved 7.0% on a reported basis and 4.4% on a core basis versus the year-ago quarter, even after factoring in a major U.S. snowstorm that briefly turned the quarter into a weather forecast rather than a demand forecast. The ticker A continues to trade in a world where EPS and revenue forecast expectations matter more than calendar quirks.

What happened in the quarter

Revenue for the quarter came in at $1.80 billion, with the company citing 7.0% year-over-year growth on a reported basis and 4.4% core growth. GAAP net income was $305 million, translating to EPS of $1.07. On a non-GAAP basis, Agilent reported net income of $386 million and non-GAAP EPS of $1.36, up about 4% from the first quarter of 2025. Management framed the results as solid execution in a healthy but dynamic market environment, even as adverse weather briefly tempered activity in the quarter.

Guidance and revenue forecast for FY26

Looking ahead, Agilent raised its full-year revenue forecast to a range of $7.3 billion to $7.5 billion, implying mid-to-high single-digit growth on a reported basis and roughly 4% to 6% core growth. The company also provided a FY26 non-GAAP EPS range of $5.90 to $6.04. For the second quarter, revenue is expected to be between $1.79 billion and $1.82 billion, with non-GAAP EPS guidance between $1.39 and $1.42.

What this might portend for Agilent and its peers

The headline here isn’t a flashy beat or a surprise miss; it’s a confirmation that Agilent’s core instrument business remains a steady engine in a sector that has more “work” than patience in some pockets. The Q1 numbers show a clean lift in both GAAP and non-GAAP metrics, underscored by a modest but meaningful upgrade to the revenue forecast and EPS range for FY26. When you translate this into the street language of earnings estimates, the guidance sets a fetchable target for analysts’ EPS consensus and for investors looking to tilt toward labs and life-science tools producers.

For sector peers, the message is simple: demand for analytical instrumentation and related consumables continues to hold up in a world chasing drug development, clinical testing, and manufacturing quality control. The snowstorm reminder is a reminder, not a rule: quarterly results can bend around one-off disruptions, but durable revenue growth and disciplined expense management tend to show up in the long run. If Agilent can sustain mid-single-digit core growth and progressed leverage on non-GAAP margins, peers with similar exposure may see more resilience than mixed-cycle expectations would imply.

Thinking aloud: interpretation and implications

The juxtaposition of a solid top-line beat with a deliberate and guided uplift in the FY26 revenue forecast suggests management’s view that demand will remain constructive, supported by ongoing investments in biotech and pharmaceutical R&D. The divergence between GAAP and non-GAAP performance—while not unusual—highlights the ongoing impact of non-operational items on reported figures; investors should watch how this gap evolves as the year unfolds.

In terms of EPS, the pathway from $1.07 GAAP to a non-GAAP range of $5.90–$6.04 for the year implies continued margin discipline and potential mix benefits from higher-margin products or services. If Agilent can sustain mid-single-digit core growth and keep cost expansion in check, the EPS trajectory may align with and perhaps modestly exceed expectations depending on end-market momentum and any currency or procurement headwinds.

Bottom line for investors

Agilent’s Q1 results are a focused reminder that the science economy is still a thing, and the company is positioned to capture a fair share of it. The revenue forecast and EPS guidance signal management’s confidence in a stable to improving operating environment for the balance of FY26. For the stock and its peers, the takeaway is less about a single quarter’s surprise and more about whether the sector can sustain the underlying demand drivers—drug discovery, clinical testing, and quality-assurance workflows—through the rest of the year. In other words, it’s less about a flash in the pan, more about a steady lantern in a long corridor.